Alnylam Pharmaceuticals
Pioneer in RNA interference (RNAi) therapeutics, developing and commercializing siRNA-based medicines for genetic diseases, cardio-metabolic diseases, and infectious diseases.
Website
https://www.alnylam.comLocation
Cambridge, Massachusetts, USA
Founded
2002
Investors
2
Categories
biotech, rna-therapeutics, rnai, genetic-medicine, pharma
Notes
Alnylam Pharmaceuticals is the leading RNAi therapeutics company and a pioneer in translating RNA interference into a new class of innovative medicines. The company has developed multiple FDA-approved RNAi drugs and has a robust pipeline addressing genetic diseases, cardio-metabolic conditions, and other serious illnesses.
Publicly traded on Nasdaq (ticker: ALNY), Alnylam has transformed from a research-stage company to a fully integrated biopharmaceutical company with multiple commercial products.
Team
- Yvonne Greenstreet, MBChB - Chief Executive Officer
- LinkedIn: linkedin.com/in/yvonnegreenstreet
- John Maraganore, Ph.D. - Founding CEO (2002-2021)
- Phillip Sharp, Ph.D. - Co-founder (Nobel Laureate)
- Paul Schimmel, Ph.D. - Co-founder
- Thomas Tuschl, Ph.D. - Scientific Founder
Additional Research Findings
- Backed by ARCH Venture Partners and Polaris Partners from early stages
- Publicly traded on Nasdaq (ticker: ALNY) since 2004
- FDA-approved products include:
- ONPATTRO (patisiran) - hereditary ATTR amyloidosis
- GIVLAARI (givosiran) - acute hepatic porphyria
- OXLUMO (lumasiran) - primary hyperoxaluria type 1
- AMVUTTRA (vutrisiran) - hereditary ATTR amyloidosis
- GalNAc conjugate delivery platform for liver-targeted RNAi
- Strategic collaborations with Regeneron, Roche, and others
- Over 3,000 employees globally
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| ARCH Venture Partners | Chicago, USA | biotech-focused | seedseries-a+3 | 6 |
| Polaris Partners | US | biotech-focused | - | 33 |